Farmaceutica REMEDIA S.A.

STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)

31.12.2023

31.12.2022

Net turnover

NOTE 4

593.358.927

535.850.640

Income from the sale of goods

589.976.173

530.960.392

Commercial discounts granted

-2.202.020

-2.799.654

Income from services provided and rents

5.584.773

7.689.902

Other operating income

4.921.303

3.350.123

OPERATING INCOME - TOTAL

598.280.230

539.200.763

Expenses with materials

NOTE 5

547.527.853

491.419.460

Expenses regarding goods

555.927.973

495.526.556

Commercial discounts received

-11.009.494

-8.770.460

Expenses with raw materials and consumables

1.539.879

3.485.778

Other expenses with materials (inventory objects)

138.925

142.418

Energy and water expenses

930.570

1.035.168

Expenses with personnel

NOTE 6

20.619.788

22.132.735

Salaries and allowances

17.707.353

19.309.357

Expenses with insurance and social protection

886.176

903.217

Other personnel expenses

2.026.259

1.920.161

Amortisations and provisions

5.548.329

4.067.397

Amortisations

5.058.187

4.016.528

Net provisions

425.051

-279.307

Losses from receivables

65.092

330.175

Other operating expenses

NOTE 7

16.428.569

14.835.225

Expenses on external services

12.592.973

10.711.430

Expenses with other taxes, charges and assimilated payments

2.500.207

1.934.291

Other expenses

1.335.389

2.189.505

OPERATING EXPENSES - TOTAL

590.124.539

532.454.817

OPERATING RESULT

8.155.691

6.745.946

Financial income

NOTE 8

1.298.237

844.833

Interest income

869.372

386.605

Income from exchange rate differences

102.132

99.868

Income from dividends

68.305

79.826

Advance payment discounts

258.428

257.985

Other financial income

20.549

Financial expenses

NOTE 8

545.353

532.927

Expenses regarding interests leasing

53.571

99.822

Operational leasing interests

67.988

62.476

Expenses due to exchange rate differences

143.570

179.995

Discounts received in advance

0

172.434

Other financial expenses

0

18.200

Other financial expenses - share of the loss from investments accounted for using the equity method

280.224

FINANCIAL RESULT

752.884

311.906

TOTAL INCOME

599.578.467

540.045.595

TOTAL EXPENSES

590.669.892

532.987.744

GROSS RESULT

NOTE 9

8.908.575

7.057.852

Profit tax

1.706.927

1.248.719

TOTAL NET PROFIT of which distributable

7.201.648

5.809.133

Shareholders of the company

7.201.648

5.809.133

Minority interest

Other elements of comprehensive income

Revaluation of tangible assets

Tax related to other elements of comprehensive income

Minority interest

COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which attributable:

7.201.648

5.809.133

Shareholders of the company

7.201.648

5.809.133

Minority interest

Earnings per share (in Lei)

- basic

0,0754

0,0608

- diluted

0,0754

0,0608

* retreated according to IFRS 16

Chairman of the Board of Administrators "TARUS" - Valentin Norbert TARUS e.U.

by representative

Valentin - Norbert TARUS

Farmaceutica REMEDIA S.A.

STATEMENT OF FINANCIAL POSITION - consolidated (Lei)

31.12.2023

31.12.2022

ASSETS

Fixed assets

46.768.058

44.484.546

Tangible assets

NOTE 10

27.159.628

24.760.379

Real estate investments

16.364.407

16.545.703

Assets related to the rights of use of leased assets

1.939.283

1.002.094

Software licences

NOTE 11

553.105

109.054

Pharmacy licences

NOTE 11

628.255

689.200

Participations held in group companies

NOTE 12

0

588.620

Participations held in companies outside the group

NOTE 12

5.916

5.916

Investments in jointly controlled entities accounted for using the equity method

21.509

Deposits and guarantees paid

NOTE 12

95.955

783.580

Current assets

268.433.018

240.890.648

Stocks

NOTE 13

44.334.576

46.262.314

Trade receivables

NOTE 14

184.264.742

173.704.309

Other receivables

5.335.665

2.840.680

Cash and cash equivalents

NOTE 15

34.498.036

18.083.345

Accrued expenses

560.447

829.696

TOTAL ASSETS

315.761.523

286.204.891

EQUITIES AND DEBTS

Equities

70.859.551

68.433.434

Share capital

NOTE 16

9.860.311

9.860.311

Share premiums

757.485

757.485

Reserves

NOTE 17

40.960.056

39.953.756

Current result

7.201.648

5.809.133

Retained earnings

NOTE 19

15.231.167

12.477.605

Retained earnings - retreatment

-890.120

-312.229

Profit distribution

0

0

Own shares

NOTE 21

-2.260.996

-112.628

Long-term debts

5.447.865

3.175.842

Debts from long term leasing

NOTE 22

1.199.792

Debts from operational leasing

Provisions

NOTE 23

Debts with deferred income tax

4.248.073

3.175.842

Current debts

239.454.107

214.595.615

Bank loans

NOTE 24

Debts from financial leasing

421.384

Debts from operational leasing

932.428

777.861

Suppliers and other similar debts

235.343.070

209.969.435

Provisions

440.784

217.307

Current tax debts

325.137

155.049

Other short-term debts

NOTE 25

2.412.688

3.054.580

Total debts

244.901.972

217.771.457

TOTAL EQUITIES AND DEBTS

315.761.523

286.204.891

* retreated according to IFRS 16

Chairman of the Board of Administrators "TARUS" - Valentin Norbert TARUS e.U.

by representative

Valentin - Norbert TARUS

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Farmaceutica REMEDIA SA published this content on 25 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2024 21:42:20 UTC.